Clinical Trials Logo

Clinical Trial Summary

This study is to allow access to crizotinib who were treated in previous Pfizer-sponsored studies in China.


Clinical Trial Description

This study is a phase 4 study, to continually access Xalkori to Chinese patients who were recruited in previous studies of Crizotinib in China, and only collect the safety data. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03672643
Study type Interventional
Source Pfizer
Contact
Status Terminated
Phase Phase 4
Start date January 28, 2019
Completion date September 28, 2023